ARC welcomed Jan Griffin, MD, amyloidosis cardiologist at the Medical University of South Carolina. Dr. Griffin discussed how ATTR affects the heart and explored advances in treatments for ATTR-CM.
She explained the medications currently available, how they work, how doctors know if they’re helping, and what new treatments are coming in the future.
The webinar concluded with a Q&A session.
Original Presentation Date:
June 10, 2025.
0:00 — Welcome
3:47 — Introduction
6:07 — ATTR Cardiac Amyloidosis Overview
TTR Stabilizers
10:58 — Vyndamax® / Vyndaqel® (tafamidis)
14:53 — Attruby™ (acoramidis)
TTR Silencers
19:18 — Amvuttra® (vutrisiran)
22:31 — Eplontersen
Gene Editing
25:14 — Nex-z (NTLA-2001)
29:44 — MAGNITUDE Study
Depleting TTR
31:54 — ALXN2220 (NI006)
36:08 — Coramitug (NNC6019/PRX004)
Prevention
37:55 — ACT-EARLY Trial
39:42 — Summary of ATTR Cardiac Therapies
40:53 — Combination Therapy
45:50 — How to Choose Initial Therapy
49:16 — Adjunctive Therapies for Heart Failure
53:52 — ARC Summary of Approved Treatments for ATTR-CM
54:47 — Q&A Session
55:03 — If I’m on one treatment, how should I go about considering other treatments?
57:36 — How often is Amvuttra® (vutrisiran) administered?
57:57 — How does Vitamin A function with reduced TTR?
59:21 — Where and how can I access gene editing treatments?
1:01:00 — When might some of the treatments currently under investigation become available?
1:03:01 — How frequently should I have my biomarkers and medical imaging monitored?
1:04:51 — What are the side effects/risks of taking tafamidis?
1:05:53 — Conclusion
Contact ARC:
Call +1 (617) 467-5170
Email ARC at support@arci.org
